For more VICC news, visit their website »
Improved therapies have led to a spike in the number of people living with cancer, and today there are more than 15.5 million survivors in the United States. However, some of these therapies can cause toxicities to the heart, the vessels and the body’s metabolism.
Vanderbilt researchers have determined that a previously uncharacterized protein responds to DNA replication stress and has an essential role in maintaining the integrity of the genome.
Vanderbilt-Ingram Cancer Center (VICC) is leading a Phase 3 global trial of a cancer therapy that was initially tested and validated in a VICC research laboratory. One of the first patients treated with the therapy came to VICC after a bump on the head led to an unexpected cancer diagnosis.
One in eight women will be diagnosed with breast cancer in their lifetime and those cancers are often detected through screening mammograms. A mammogram is a low-dose X-ray of the breast that enables an imaging specialist to look for changes in breast tissue that could indicate cancer.
Scientists in the Vanderbilt Epidemiology Center (VEC) and Vanderbilt-Ingram Cancer Center (VICC) have been awarded a grant to plan and develop a Regional Center of Research Excellence in non-communicable diseases in Vietnam.
Vanderbilt-Ingram Cancer Center’s 2016 Cancer Survivorship Celebration will be held Sunday, Nov. 6, from 2 to 4 p.m. The annual event is being hosted in partnership with Monroe Carell Jr. Children’s Hospital at Vanderbilt.